CNTX — CONTEXT THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About CONTEXT THERAPEUTICS INC (CNTX)
CONTEXT THERAPEUTICS INC (CNTX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $4M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in CNTX
How many top investors track CNTX
A small number of top investors own this.
CNTX Ownership Composition
How CONTEXT THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other96.5%
- Hedge Funds3.5%
Tracked investors reporting CNTX
- Izzy EnglanderMar 31, 2026Millennium ManagementShares1.4MValue$3.7M% Portfolio0.00%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares140KValue$366.8K% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares57.2KValue$149.9K% Portfolio0.00%
Recent activity
- New$77.5KFeb 17, 2026
- New$149.9KMay 15, 2026
Frequently asked questions
- How many institutional investors hold CNTX?
- 3 tracked institutional investors disclosed a position in CNTX (CONTEXT THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of CNTX?
- Izzy Englander, Millennium Management, holds the largest disclosed position in CNTX, valued at $4M.
- Did institutional ownership of CNTX increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 fully exited CNTX.
- Where does this CNTX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.